表达HPV16 L1、L2和E7蛋白的非复制重组痘苗病毒诱发的抗肿瘤免疫反应

The anti-tumor immunoresponses by unreplicable recombinant vaccinia virus expressing HPV16 L1,L2,and E7 proteins

目的:评价表达HPV16 L1、L2E7的非复制重组痘苗病毒疫苗的抗肿瘤免疫反应。方法:采用肿瘤预防、肿瘤治疗和肿瘤切除等方法,观察疫苗NTVJL1/L2E7的抗肿瘤效果,用酶联免疫斑点(ELISPOT)和CTL检测该疫苗在小鼠体内诱发的细胞免疫应答。结果:在肿瘤预防和肿瘤治疗试验中,疫苗可以分别使60%和50%的小鼠免受HPV16阳性的治疗细胞攻击,肿瘤切除试验中,疫苗可以使70%的小鼠免于肿瘤复发,与对照组之间的差异具有显著性。ELISPOT和CTL均检测出强的特异性细胞免疫水平。结论:NTVJL1/L2E7能够在小鼠体内诱发出理想的抗肿瘤免疫反应,可以作为防治宫颈癌的候选疫苗。

Objective：To evaluate the anti-tumor immune responses of nureplicable recombinant vaecinia virus-based vaccine expressing HPVI6 L1 and 12E7 proteins. Methods： The anti-lumor effects of the vaccine were observed using mouse models of prophylactic, therapeutic and tumor excision. The cell-mediated immunity induced by the vaccine was assessed by enzyme-linked immnnospot （ELIPOT） and eytotoxic T lymphocye （CTL） assay. Results：The vaccine could protect 60% and 50% mice from the challenge of HPV16-positive tumor cells in prophylactic and therapeutic mouse model, respectively. It could protect from recurrence of the tumor in 70% mice of the excision model. The differences aroong the groups were significant. Strongly specific cell-mediated immunity was found using ELISPOT and CTL assay. Conclusion： The ideal anli-tumor immune respoases can be induced by NTVJL1/L2E7 vaccine in mice and it can be considered to be one candidate vaccine of cervical cancer.